AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease (Q34147757)

31 July 2017

AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease (English)

1 reference

31 July 2017

0 references

Abraham Fisher

1

1 reference

31 July 2017

Rachel Brandeis

2

1 reference

31 July 2017

Rachel Haring Nira Bar-Ner

3

1 reference

31 July 2017

Michal Kliger-Spatz

4

1 reference

31 July 2017

Niva Natan

5

1 reference

31 July 2017

Hagar Sonego

6

1 reference

31 July 2017

Itzhak Marcovitch

7

1 reference

31 July 2017

Zipora Pittel

8

1 reference

31 July 2017

1 August 2002

1 reference

Journal of Molecular Neuroscience

31 July 2017

1 reference

31 July 2017

19

1 reference

31 July 2017

1-2

1 reference

31 July 2017

145-153

1 reference

https://scigraph.springernature.com/pub.10.1007/s12031-002-0025-3

31 July 2017

0 references

cites work

Activation of protein kinase C inhibits cellular production of the amyloid beta-protein

1 reference

12 December 2020

Activation of m1 muscarinic acetylcholine receptor regulates tau phosphorylation in transfected PC12 cells

1 reference

12 December 2020

Muscarinic agonists reduce tau phosphorylation in non-neuronal cells via GSK-3beta inhibition and in neurons.

1 reference

12 December 2020

Reduction of cerebrospinal fluid amyloid beta after systemic administration of M1 muscarinic agonists

1 reference

12 December 2020

Characterization of muscarinic receptor subtypes in Alzheimer and control brain cortices by selective muscarinic antagonists

1 reference

12 December 2020

Site-specific dephosphorylation of tau of apolipoprotein E-deficient and control mice by M1 muscarinic agonist treatment.

1 reference

12 December 2020

Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor

1 reference

12 December 2020

Amyloid beta-peptide disrupts carbachol-induced muscarinic cholinergic signal transduction in cortical neurons.

1 reference

12 December 2020

Quantitative analysis of tau protein-immunoreactive accumulations and beta amyloid protein deposits in the cerebral cortex of the mouse lemur, Microcebus murinus.

1 reference

12 December 2020

Alzheimer's disease: relationship between muscarinic cholinergic receptors, beta-amyloid and tau proteins.

1 reference

12 December 2020

Regulated secretion of beta-amyloid precursor protein in rat brain

1 reference

12 December 2020

Muscarinic agonists for the treatment of Alzheimer's disease: progress and perspectives.

1 reference

12 December 2020

Muscarinic regulation of Alzheimer's disease amyloid precursor protein secretion and amyloid beta-protein production in human neuronal NT2N cells

1 reference

12 December 2020

NGF promotes amyloid precursor protein secretion via muscarinic receptor activation

1 reference

12 December 2020

The selective muscarinic M1 agonist AF102B decreases levels of total Abeta in cerebrospinal fluid of patients with Alzheimer's disease.

1 reference

12 December 2020

Carbachol blocks beta-amyloid fragment 31-35-induced apoptosis in cultured cortical neurons

1 reference

12 December 2020

AF102B, a novel M1 agonist, enhanced spatial learning in C57BL/10 mice with a long duration of action

1 reference

12 December 2020

Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors

1 reference

12 December 2020

Muscarinic M1 receptor agonists increase the secretion of the amyloid precursor protein ectodomain

1 reference

12 December 2020

M1 muscarinic agonist treatment reverses cognitive and cholinergic impairments of apolipoprotein E-deficient mice.

1 reference

12 December 2020

M1 muscarinic receptors block caspase activation by phosphoinositide 3-kinase- and MAPK/ERK-independent pathways

1 reference

12 December 2020

Increased levels of tau protein in SH-SY5Y cells after treatment with cholinesterase inhibitors and nicotinic agonists

1 reference

12 December 2020

Treatment with the selective muscarinic agonist talsaclidine decreases cerebrospinal fluid levels of total amyloid beta-peptide in patients with Alzheimer's disease.

1 reference

12 December 2020

Muscarinic control of amyloid precursor protein secretion in rat cerebral cortex and cerebellum.

1 reference

12 December 2020

Pharmacological drug treatment of Alzheimer disease: the cholinergic hypothesis revisited.

1 reference

12 December 2020

Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice

1 reference

12 December 2020

Clinical neurochemistry: developments in dementia research based on brain bank material

1 reference

12 December 2020

Amyloid precursor protein secretion via muscarinic receptors: reduced desensitization using the M1-selective agonist AF102B

1 reference

12 December 2020

The muscarinic M1 agonist xanomeline increases soluble amyloid precursor protein release from Chinese hamster ovary-m1 cells

1 reference

12 December 2020

beta-Amyloid protein precursor in Microcebus murinus: genotyping and brain localization

1 reference

12 December 2020

Therapeutic strategies in Alzheimer's disease: M1 muscarinic agonists

1 reference

12 December 2020

NGF-dependent neurotrophic-like effects of AF102B, an M1 muscarinic agonist, in PC12M1 cells

1 reference

12 December 2020

Mitogen-activated protein kinase-dependent and protein kinase C-dependent pathways link the m1 muscarinic receptor to beta-amyloid precursor protein secretion

1 reference

12 December 2020

10.1007/S12031-002-0025-3

Identifiers

DOI

1 reference

Dimensions Publication ID

31 July 2017

0 references

1 reference